Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemiaKimmo Porkka, Francis Y. F. Lee, Martin Höglund et al.|Blood|2008Cited by 447
Increased incidence of another cancer in myeloproliferative neoplasms patients at the time of diagnosisHelna Pettersson, Björn Andréasson, Håvar Knutsen et al.|European Journal Of Haematology|2014Cited by 39
Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study GroupGunnar Birgegård, Björn Andréasson, Jan Samuelsson et al.|European Journal Of Haematology|2018Cited by 37
Genetic variation in <i><scp>IL</scp>28B</i> (<i><scp>IFNL</scp>3</i>) and response to interferon‐alpha treatment in myeloproliferative neoplasmsMarie Lindgren, Björn Andréasson, Jan Samuelsson et al.|European Journal Of Haematology|2018Cited by 23
A Retrospective Cohort Study of Interferon-α Therapy in Myeloproliferative Neoplasms; Adverse Events, Thromboembolic Incidence and Causes of Termination of TherapyMarie Lindgren, Björn Andréasson, Jan Samuelsson et al.|Blood|2014Cited by 3